Alain Baron, MD
Chief Executive Officer⟵ Back to Team
Alain Baron is a co-founder of Escient Pharmaceuticals and was named President and CEO in May of 2018. In 2010, Dr. Baron co-founded Elcelyx Therapeutics where he served as President and Chief Executive Officer during his tenure with the company. Dr. Baron was a Venture Partner at Lightstone Ventures until 2017 and previously held the role of Entrepreneur-in-Residence at its predecessor firm, Morgenthaler Ventures beginning in 2008. Previously, Dr. Baron was Senior Vice President of Research at Amylin Pharmaceuticals where he served in senior roles in R&D since 1999. He was instrumental in advancing clinical programs that have culminated in four successful endocrinology products (Byetta®, Bydureon®, Symlin® and Myalept®). Prior to joining industry, Dr. Baron had a successful academic career, most recently at Indiana University School of Medicine in Indianapolis, where he served as Professor of Medicine and Director, Division of Endocrinology and Metabolism. He has also held faculty positions in the Division of Endocrinology and Metabolism at University of California, San Diego, and the Veterans Administration Medical Center in San Diego. He is the recipient of several prestigious awards for his research in diabetes and vascular disease, including the 1996 Outstanding Clinical Investigator Award from the American Federation for Medical Research and is a Member, American Society for Clinical Investigation and the Association of American Physicians. He is also a past National Institutes of Health MERIT award recipient.